JACOBSON PHARMA (02633): ULFERTS Pharmaceuticals enters into a licensing agreement with Li Zhongsheng Hall for 2025.

12:29 28/02/2025

Jacobson Pharmaceuticals (02633) and Health Biotech (02161) jointly announced on February 28, 2025...

Jacobson Pharma (02633) and JBM Healthcare (02161) jointly announced that on February 28, 2025, Ulferts Pharmaceuticals and Lee Chung Sang Tong entered into a licensing agreement for the year 2025. Under this agreement, Ulferts Pharmaceuticals agreed to license Lee Chung Sang Tong to use part of the factory in accordance with the terms and conditions of the 2025 licensing agreement. The agreement is valid from January 28, 2025 to January 27, 2028 (including the first and last day), with a monthly license fee of HK$218,000. Mr. Samson Sum, a non-executive director, chairman, and controlling shareholder of JBM Healthcare, holds approximately 59.92% equity in Jacobson Pharma. Ulferts Pharmaceuticals is an indirect wholly-owned subsidiary of Jacobson Pharma. Therefore, Ulferts Pharmaceuticals is the contact person for Mr. Samson Sum and the associate of JBM Healthcare.

HK Stock Market Move | XTEP INT'L (01368) falls more than 3% in the afternoon, with low single-digit declines in retail sales of the main brand in the first half of the year.

Morgan Stanley: Expects BYD COMPANY (01211) to have a strong recovery in the second quarter, with net profit rebounding to 9 billion RMB.

New stocks outlook | Zhiyuan Pharmaceutical: "Internet celebrity acne treatment" aura fades, and the combination of declining profits and research and development shortcomings squeezes valuation logic.

HK Stock Market Move | XTEP INT'L (01368) falls more than 3% in the afternoon, with low single-digit declines in retail sales of the main brand in the first half of the year.

Morgan Stanley: Expects BYD COMPANY (01211) to have a strong recovery in the second quarter, with net profit rebounding to 9 billion RMB.